263 related articles for article (PubMed ID: 28554233)
1. Hyaluronic acid and Arg-Gly-Asp peptide modified Graphene oxide with dual receptor-targeting function for cancer therapy.
Guo Y; Xu H; Li Y; Wu F; Li Y; Bao Y; Yan X; Huang Z; Xu P
J Biomater Appl; 2017 Jul; 32(1):54-65. PubMed ID: 28554233
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery.
Song E; Han W; Li C; Cheng D; Li L; Liu L; Zhu G; Song Y; Tan W
ACS Appl Mater Interfaces; 2014 Aug; 6(15):11882-90. PubMed ID: 25000539
[TBL] [Abstract][Full Text] [Related]
3. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells.
Cai LL; Liu P; Li X; Huang X; Ye YQ; Chen FY; Yuan H; Hu FQ; Du YZ
Int J Nanomedicine; 2011; 6():3499-508. PubMed ID: 22282676
[TBL] [Abstract][Full Text] [Related]
4. Folic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy.
Ma N; Liu J; He W; Li Z; Luan Y; Song Y; Garg S
J Colloid Interface Sci; 2017 Mar; 490():598-607. PubMed ID: 27923144
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid nanogels prepared via ortho ester linkages show pH-triggered behavior, enhanced penetration and antitumor efficacy in 3-D tumor spheroids.
Yang G; Fu S; Yao W; Wang X; Zha Q; Tang R
J Colloid Interface Sci; 2017 Oct; 504():25-38. PubMed ID: 28527297
[TBL] [Abstract][Full Text] [Related]
6. Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride.
Zhang B; Yang X; Wang Y; Zhai G
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():198-206. PubMed ID: 28415455
[TBL] [Abstract][Full Text] [Related]
7. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
8. Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery.
Yang H; Bremner DH; Tao L; Li H; Hu J; Zhu L
Carbohydr Polym; 2016 Jan; 135():72-8. PubMed ID: 26453853
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
10. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
12. Photoresponsive fluorescent reduced graphene oxide by spiropyran conjugated hyaluronic acid for in vivo imaging and target delivery.
Nahain AA; Lee JE; Jeong JH; Park SY
Biomacromolecules; 2013 Nov; 14(11):4082-90. PubMed ID: 24106989
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery.
Miao W; Shim G; Kang CM; Lee S; Choe YS; Choi HG; Oh YK
Biomaterials; 2013 Dec; 34(37):9638-47. PubMed ID: 24016852
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional hyaluronic acid modified graphene oxide loaded with mitoxantrone for overcoming drug resistance in cancer.
Hou L; Feng Q; Wang Y; Yang X; Ren J; Shi Y; Shan X; Yuan Y; Wang Y; Zhang Z
Nanotechnology; 2016 Jan; 27(1):015701. PubMed ID: 26595807
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
Wang C; Li Y; Chen B; Zou M
Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
[TBL] [Abstract][Full Text] [Related]
16. Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.
Mansur AAP; Carvalho SM; Lobato ZIP; Leite MF; Cunha ADS; Mansur HS
Bioconjug Chem; 2018 Jun; 29(6):1973-2000. PubMed ID: 29790738
[TBL] [Abstract][Full Text] [Related]
17. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
Wang K; Zhang X; Zhang L; Qian L; Liu C; Zheng J; Jiang Y
Drug Deliv; 2015 May; 22(3):389-99. PubMed ID: 24670095
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.
Dicheva BM; ten Hagen TL; Seynhaeve AL; Amin M; Eggermont AM; Koning GA
Pharm Res; 2015 Dec; 32(12):3862-76. PubMed ID: 26202516
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
20. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
